Nano to Micro Delivery Systems: Targeting Angiogenesis in Brain Tumors

Overview

Journal J Angiogenes Res

Publisher Biomed Central

Date 2010 Oct 12

PMID 20932320

Citations 8

Authors

Ariel Gilert

Marcelle Machluf

Affiliations

Soon will be listed here.

Abstract

Treating brain tumors using inhibitors of angiogenesis is extensively researched and tested in clinical trials. Although anti-angiogenic treatment holds a great potential for treating primary and secondary brain tumors, no clinical treatment is currently approved for brain tumor patients. One of the main hurdles in treating brain tumors is the blood brain barrier - a protective barrier of the brain, which prevents drugs from entering the brain parenchyma. As most therapeutics are excluded from the brain there is an urgent need to develop delivery platforms which will bypass such hurdles and enable the delivery of anti-angiogenic drugs into the tumor bed. Such delivery systems should be able to control release the drug or a combination of drugs at a therapeutic level for the desired time. In this mini-review we will discuss the latest improvements in nano and micro drug delivery platforms that were designed to deliver inhibitors of angiogenesis to the brain.

Citing Articles

How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.

Mohapatra P, Gopikrishnan M, C G, Chandrasekaran N Int J Nanomedicine. 2024; 19:2441-2467.

PMID: 38482521 PMC: 10932758. DOI: 10.2147/IJN.S442520.

Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders.

Waris A, Ali A, Khan A, Asim M, Zamel D, Fatima K Nanomaterials (Basel). 2022; 12(13).

PMID: 35807977 PMC: 9268720. DOI: 10.3390/nano12132140.

Lab-On-A-Chip for the Development of Pro-/Anti-Angiogenic Nanomedicines to Treat Brain Diseases.

Subramaniyan Parimalam S, Badilescu S, Sonenberg N, Bhat R, Packirisamy M Int J Mol Sci. 2019; 20(24).

PMID: 31817343 PMC: 6940944. DOI: 10.3390/ijms20246126.

Sizes and Sufficient Quantities of MSC Microspheres for Intrathecal Injection to Modulate Inflammation in Spinal Cord Injury.

Kumar S, Babiarz J, Basak S, Kim J, Barminko J, Gray A Nano Life. 2018; 5(4).

PMID: 29545904 PMC: 5849255. DOI: 10.1142/S179398441550004X.

A novel preparation method for drug nanocrystals and characterization by ultrasonic spray-assisted electrostatic adsorption.

Gao B, Wang J, Wang D, Zhu Z, Qiao Z, Yang G Int J Nanomedicine. 2013; 8:3927-35.

PMID: 24143097 PMC: 3798150. DOI: 10.2147/IJN.S48597.

References

Deguchi T, Isozaki K, Yousuke K, Terasaki T, Otagiri M . Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier. J Neurochem. 2006; 96(4):1051-9. DOI: 10.1111/j.1471-4159.2005.03550.x. View

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

Jouan V, Canron X, Alemany M, Caen J, Quentin G, Plouet J . Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood. 1999; 94(3):984-93. View

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

Wolburg H, Lippoldt A . Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol. 2003; 38(6):323-37. DOI: 10.1016/s1537-1891(02)00200-8. View

Minchinton A, Tannock I . Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583-92. DOI: 10.1038/nrc1893. View

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

Hammang J, Emerich D, Winn S, Lee A, Lindner M, Gentile F . Delivery of neurotrophic factors to the CNS using encapsulated cells: developing treatments for neurodegenerative diseases. Cell Transplant. 1995; 4 Suppl 1:S27-8. DOI: 10.1016/0963-6897(94)00069-v. View

Acharya R, Sundareshan M . Development of optimal drug administration strategies for cancer-chemotherapy in the framework of systems theory. Int J Biomed Comput. 1984; 15(2):139-50. DOI: 10.1016/0020-7101(84)90026-6. View

10.

Cappuccio A, Elishmereni M, Agur Z . Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res. 2006; 66(14):7293-300. DOI: 10.1158/0008-5472.CAN-06-0241. View

11.

Lindvall O, Wahlberg L . Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp Neurol. 2007; 209(1):82-8. DOI: 10.1016/j.expneurol.2007.08.019. View

12.

Ranganath S, Kee I, Krantz W, Chow P, Wang C . Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy. Pharm Res. 2009; 26(9):2101-14. DOI: 10.1007/s11095-009-9922-2. View

13.

Emerich D, Winn S, Hantraye P, Peschanski M, Chen E, Chu Y . Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature. 1997; 386(6623):395-9. DOI: 10.1038/386395a0. View

14.

Visted T, Bjerkvig R, Enger P . Cell encapsulation technology as a therapeutic strategy for CNS malignancies. Neuro Oncol. 2001; 3(3):201-10. PMC: 1920619. DOI: 10.1093/neuonc/3.3.201. View

15.

Zhu S, Hong M, Zhang L, Tang G, Jiang Y, Pei Y . PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res. 2009; 27(1):161-74. DOI: 10.1007/s11095-009-9992-1. View

16.

Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina S, Engelhardt B . Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res. 2003; 20(3):409-16. DOI: 10.1023/a:1022604120952. View

17.

Zhao S, Zhang X, Zhang J, Zhang J, Zou H, Liu Y . Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains. J Chemother. 2008; 20(2):253-62. DOI: 10.1179/joc.2008.20.2.253. View

18.

Garcia P, Youssef I, Utvik J, Florent-Bechard S, Barthelemy V, Malaplate-Armand C . Ciliary neurotrophic factor cell-based delivery prevents synaptic impairment and improves memory in mouse models of Alzheimer's disease. J Neurosci. 2010; 30(22):7516-27. PMC: 6632372. DOI: 10.1523/JNEUROSCI.4182-09.2010. View

19.

Riina H, Fraser J, Fralin S, Knopman J, Scheff R, Boockvar J . Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma. J Exp Ther Oncol. 2010; 8(2):145-50. View

20.

Lagarce F, Garcion E, Faisant N, Thomas O, Kanaujia P, Menei P . Development and characterization of interleukin-18-loaded biodegradable microspheres. Int J Pharm. 2006; 314(2):179-88. DOI: 10.1016/j.ijpharm.2005.07.029. View